Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The Role of IL5 in Epithelial Cell Integrity
NCT05895929
Recruiting
The goal of this laboratory study is the examine the effect of mepolizumab drug on the health and function of the cells lining the human nasal airways in vitro cell culture derived from patients with chronic rhinosinusitis with nasal polyposis. The main questions the study aims to study are: 1. To see what mepolizumab does to suppress inflammation of the human cells. 2. To see what mepolizumab does to maintain barrier integrity of epithelial cells
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/04/2025
Locations: Johns Hopkins Bayview Medical Center, Baltimore, Maryland
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)
Register for Updates
Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET
NCT05609552
Recruiting
This is an observational study that will examine the pretomanid pharmacokinetics (PK) in tuberculosis (TB) patients. Dynamic 18F-pretomanid PET/CT will be performed after intravenous injection of 18F-pretomanid to determine multi-compartment, noninvasive determination of pretomanid PK in TB patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Tuberculosis
Register for Updates
APrevent-VOIS-Implant-002 - a Two-Part, Open-Label, Non-Randomized Multicenter Study
NCT05119842
Recruiting
This is a prospective, 2-part, multi-center, open-label, non-randomized clinical trial to assess safety and effectiveness of APrevent® VOIS Implants for the treatment of patients with Unilateral Vocal Fold Paralysis (UVFP). In total 30 evaluable patients are planned to be enrolled.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/04/2025
Locations: Greater Baltimore Medical Center, Baltimore, Maryland
Conditions: Paralysis, Unilateral, Vocal Cord
Register for Updates
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
NCT04620239
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: The Johns Hopkins Hospital, The Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Register for Updates
Safety for Home Administration of Microdose Psilocybin Use
NCT06450210
Recruiting
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
02/03/2025
Locations: 5510 Nathan Shock Drive, Baltimore, Maryland
Conditions: Psychedelic Experiences
Register for Updates
A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806
Recruiting
The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Maryland Oncology Hematology - Independent of SCRI/ US Oncology, Columbia, Maryland
Conditions: Myelofibrosis, Moderate Thrombocytopenia
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Johns Hopkins, Baltimore, Maryland
Conditions: Coronary Artery Disease
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Maryland Oncology & Hematology, P.A., Rockville, Maryland
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Maryland Oncology Hematology-Satellite, Annapolis, Maryland
Conditions: Myelofibrosis
Register for Updates
Study Assessing CLENPIQ As Bowel Preparation for Pediatric Colonoscopy
NCT04113382
Recruiting
Bowel preparation for pediatric colonoscopy.
Gender:
ALL
Ages:
Between 2 years and 8 years
Trial Updated:
02/03/2025
Locations: Ferring Investigational Site, Baltimore, Maryland
Conditions: Bowel Preparation
Register for Updates
AMI Construction in Lower Extremity Residual Limbs
NCT04063592
Recruiting
This study will involve the development of a novel approach to lower extremity residual limb surgical revision that offers the promise of augmenting volitional motor control, restore proprioception and reverse atrophy
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Amputation
Register for Updates
A Novel Approach to Upper Extremity Amputation to Augment Volitional Control and Restore Proprioception
NCT03882073
Recruiting
The hypothesis of this research protocol is that the investigators will be able to redesign the manner in which upper limb amputations are performed so as to enable volitional control of next generation prosthetic devices and restore sensation and proprioception to the amputated limb. The investigators will test this hypothesis by performing modified above elbow or below elbow amputations in ten intervention patients, and compare their outcomes to ten control patients who have undergone traditio... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: Walter Reed National Military Medical Center, Bethesda, Maryland
Conditions: Amputation
Register for Updates